Healthcare
Centessa Pharmaceuticals plc American Depositary Receipt(CNTA)
Live Price
Offline$40.02
+0.38% today
1Y Change
+195.98%
Window
Jun 25, 2025 โ Jun 16, 2026
- Market Cap
- $5.92B
- Revenue Growth
- 0.0%
- EPS Growth
- +29.1%
- Dividend Yield
- 0.0%
Coverage: 245 bars ยท Jun 25, 2025 โ Jun 16, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Centessa Pharmaceuticals plc American Depositary Receipt (CNTA) is a Healthcare stock with a market cap of $5.92B and listed on NASDAQ. The stock last traded around $40.02 and up 196.0% across the available one-year price window (Jun 25, 2025 โ Jun 16, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +29.1%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +29.1%, free cash flow -36.7% with operating margin 0.0% and ROIC -42.4%. Stock Foundry combines CNTA price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 14, 2026, but the surprise data is still limited.
The setup is mixed rather than one-directional
Revenue is 0.0% and EPS is +29.1%, while operating margin sits near 0.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +6.2% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 14, 2026 | โ | -0.0% | +0.5% | +0.3% |
2026 Mar 31, 2026 | -29.7% | +0.4% | -0.5% | -0.7% |
2025 Nov 5, 2025 | -5.1% | +1.4% | +18.6% | +31.3% |
Benchmark Edge
CNTA vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
CNTA
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
CNTA Max Drawdown
-26.38%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for CNTA and SPY.
Company Overview
Centessa Pharmaceuticals plc American Depositary Receipt
NASDAQ
Centessa Pharmaceuticals plc American Depositary Receipt represents shares in Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company headquartered in Altrincham, United Kingdom, and founded in 2020. The company discovers and develops innovative medicines to address high unmet needs in various therapeutic areas, including oncology, hematology, immunology, inflammation, neuroscience, and rare diseases. Its pipeline features a diverse portfolio of uncorrelated programs ranging from preclinical to Phase 3 stages, such as SerpinPC targeting Hemophilia A and B, LB101 for solid tumors, ORX750 for Narcolepsy Type 1 and other sleep disorders, MGX292 for Pulmonary Arterial Hypertension, and additional undisclosed assets for solid tumors. ORX142, a novel Orexin Receptor 2 agonist, is advancing in clinical development with recent FDA clearance for Phase 1 studies. Centessa Pharmaceuticals plc focuses on delivering transformational therapies through its integrated platform, emphasizing orexin receptor agonists and other novel mechanisms to treat complex diseases like sleep disorders and beyond.
- Leadership
- Dr. Mario Alberto Accardi Ph.D.
- Employees
- 118
- Street Address
- 1 Ashley Road, 3rd Floor
- Mailing
- Altrincham, WA14 2DT
- Region
- Altrincham, United Kingdom
- Last Updated
- May 8, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- โ
- Price/Book
- 12.5
Growth
- Revenue
- 0.0%
- EPS
- +29.1%
- Free Cash Flow
- -36.7%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- -60.4%
- ROIC
- -42.4%
Balance Sheet
- Debt/Equity
- 0.02
- Current Ratio
- 9.53
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.